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doi:10.1016/j.ejvs.2010.08.016Abstract Introduction: Endovascular procedures for repair of Type B aortic dissection have
become increasingly common and are often considered to be first line therapy for acute
complicated dissections. The long term durability of these repairs is largely undefined.
Methods: The Virtue Registry is a prospective, non-randomised, multi centre European Clinical
Registry designed to inform on the clinical and morphological outcomes of 100 patients with
Type B aortic dissection treated with the Medtronic Valiant thoracic stent graft. Patients with
acute, sub-acute and chronic Type B dissections will be prospectively followed for three years.
Clinical outcomes and aortic morphology will be defined.
Results: Fifty patients had an acute dissection, 24 a sub-acute dissection and 26 a chronic
lesion. The 30-day mortality for the acute, sub-acute and chronic lesions was 8%, 0% and
0%. The in hospital composite outcome (mortality, stroke or paraplegia) for the three groups
was 16%, 0% and 3.8% respectively. The effect of left subclavian artery (LSCA) revascularisation
was defined with the composite endpoint of patients with a covered, non-revascularised LSCA
being 20% as compared to 5.8% in the covered, revascularised group.
Conclusion: The early outcomes for the treatment of Type B aortic dissection are reported in
the Virtue Registry. Longer term follow-up is planned to report on clinical and morphological
outcomes up to 36 months post-procedure.
ª 2010 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.n, Tel.: þ44 208 725 3205;
georges.nhs.uk.
investigator and number of
.
lsevier Ltd on behalf of EuropeanIntroduction
Each year in Europe an estimated sixteen thousand people
are diagnosed with descending thoracic aortic pathology.
Endovascular stent grafts promise a minimally invasive
approach for the management of thoracic aortic disease
and contemporary results suggest that endovascular
procedures may be utilised as first line therapy for many
thoracic aortic pathologies.1 The literature for the endo-
vascular treatment of the thoracic aorta is not well formedSociety for Vascular Surgery.
160 The VIRTUE Registry Investigatorsat the present time with the majority of reports being case
series or registry data, containing information that mixes
different pathologies and different presentations.
Despite the relative infancy of thoracic endografting,
these procedures are now routinely used in the treatment
of Type B aortic dissection. The early results of endovas-
cular treatment of acute complicated Type B dissections
are reasonably well characterized and suggest a substantial
early mortality advantage over open surgical treatment.2,3
Less certain is the place of endovascular therapy for
chronic Type B dissections or in lesions that may be clas-
sified as sub-acute (between 2 and 6 weeks after the onset
of dissection). There is a relatively sparse literature
reporting the outcomes of endovascular therapy in non-
acute dissections.
The majority of contemporary reports detail the acute
outcomes of endovascular therapy in Type B aortic dissec-
tion but the long term outcomes are less well character-
ized. The incidence of graft related complications has not
been described in sufficient detail to date and information
regarding the long term protection from aortic dilatation
and rupture is lacking. One of the fundamental differences
in the treatment of thoracic aneurysms as compared to the
treatment of Type B dissections is the ability of the aorta to
remodel following endovascular repair. There have been
some reports that suggest the aorta of acute Type B
dissection remodels more extensively than chronic dissec-
tions, but the remodelling of sub-acute dissections remains
a matter of conjecture.4
The present study was designed to evaluate the perfor-
mance of one particular endograft, the Valiant stent graft
system, in the treatment of Type B aortic dissection. The
registry will report the results of patients treated in the
acute, sub-acute and chronic phases of the disease process
and will inform on both clinical and morphological
outcomes. The registry aims to report outcomes to a follow-
up of three years. The present report details the design of
the Virtue registry, details of patients recruited and early
(30-day or in hospital) outcomes.
Methods
Study design
The Virtue registry is a prospective, non-randomised, multi
centre European Clinical Registry designed to inform on the
clinical and morphological outcomes of 100 patients with
Type B aortic dissection treated with the Medtronic Valiant
thoracic stent graft with the Xcelerant delivery system. The
study was sponsored by Medtronic. The primary endpoint of
the registry was all cause mortality at 12 months post-
procedure. Secondary end points included all cause
mortality, disease-, procedure- or device related mortality,
major complications, technical success, procedural
success, reintervention, and graft related complications.
End points will be recorded at 30 days (or the end of in
patient stay if longer), 3, 6, 12, 24 and 36 months. Aortic
morphology will be reported after analysis of cross
sectional imaging by a core laboratory.
Written informed consent was obtained prior to enroll-
ment. Patients were considered for inclusion in the registryif they had a Type B dissection amenable to endovascular
treatment and were over 18 years of age. Specific indica-
tions for inclusion were documented by the duration of the
disease and were at the investigators clinical discretion:
 Acute dissection (14 days from first dissection): aortic
rupture, malperfusion syndromes (visceral, renal, lower
limb), impending rupture (persistent pain), refractory
hypertension
 Sub-acute dissection (15e92 days): complicated/
symptomatic dissection, aortic expansion >5.5 cm,
aortic diameter >4.0 cm with true and false lumens
both patent
 Chronic dissection (>92 days): complicated/symptom-
atic dissection, aortic diameter > 5.5 cm or expanding
>0.5 cm/y
Exclusion criteria included patients with a dissection
involving the ascending aorta, penetrating ulcers and intra-
mural haematoma in the absence of dissection, ongoing
infection, an estimated life expectancy < 12 months,
documented connective tissue disease (e.g. Marfan
syndrome), and patients with a history of bleeding diathesis.
Patients were recruited from the centres detailed in.
Appendix A Patient recruitment was not consecutive but
was at the discretion of the enrolling physician, and
dependent on patient consent.
An overview of registry procedures is given in Table 1.Brief description of the Valiant stent graft and
Xcelerant delivery system5
The Valiant stent graft is composed of a woven, mono-
filament polyester graft sewn to a self-expanding nickel-
etitanium (Nitinol) wire stent. The Nitinol scaffolding is
composed of a series of 5 peaked springs stacked in
a tubular configuration and sewn with braided polyester
non-absorbable sutures onto the outside of the polyester
graft material. The proximal and distal stents differ from
the ‘body’ springs in that they have 8 peaks and range in
height from 15 to 17 mm. The endograft does not have
a connecting bar between springs in an attempt to increase
conformability of the graft. The spring spacing is designed
to allow adjacent peaks to contact each other when loaded
into the Xcelerant delivery system and provide the neces-
sary column strength for deployment. The proximal and
distal ends of the endoprosthesis come in both open (Free-
Flo) and closed (Closed Web) configurations Figs. 1 and 2.
Seven radiopaque platinumeiridium markers are sewn to
the endoprosthesis fabric. The four proximal 8 markers and
two distal 0 markers indicate the proximal and distal
extremities of the stent material. A single 8 ‘mid-marker’
indicates the minimum amount of overlap required when
deploying multiple segments. The Closed Web configuration
is not designed for use as a primary section or proximal
extension. A segment with a FreeFlo configuration should
not be deployed within another segment because of the risk
of material rupture. Valiant is currently available in
diameters from 24 mm to 46 mm. Junctions between
sections require over sizing to achieve a seal. Multiple
sections may be required to achieve disease coverage and
Table 1 Overview of registry procedures.
Pre-Procedure During
Procedue
Prior to Discharge
(Or up to 30 days
post-procedurea)
6 Months
Post-Procedure
Follow-Up
12, 24 & 36 Months
Post-Procedure
Follow-Up
Intervals 122 days to Day 0 Day 0 1e30 (þ10 Days) 180  28 Days 365, 730 &
1095  28 Days
Patient history X
Physical exam X X X X
Contrast Enhanced
CT Scan or MRI
and X-Ray
X X X X
Angiogram (X) If available per
hospital routine
X
Events X X X X
a Depending on the normal hospital schedule.
The VIRTUE Registry of Type B Thoracic Dissections 161fixation. These should be sized to give appropriate over
sizing, using tapered segments if necessary, and sufficient
length taking account of the requirement for adequate
overlap.
The Xcelerant delivery system consists of a single use,
disposable catheter with an integrated handle to provide
the user with controlled deployment of the Valiant graft.
The delivery system has a 22 to 25 French outer diameter
and is designed to track over a 0.03500 guide wire. The
delivery part of the system is composed of an inner member
with a flexible tapered tip, a middle member incorporating
the stent-stop and an outer cover. A stainless steel braid
stiffens the outer cover. The outer cover restrains the stent
graft during tracking and releases the stent graft upon
retraction. The middle member helps tracking through
tortuous anatomy and has a flexible stent-stop to maintain
the graft position during deployment. Rotating or releasing
and retracting the integrated handle deploy the endograft
by retraction of the outer sheath cover. Should the handle
jam it can be disassembled to allow direct retraction of the
outer sheath while the inner and middle members are held
firmly.
Analysis of aortic morphology
Cross sectional imaging will be analysed by a core labora-
tory (University of Utrecht) at specified time points as
detailed in Table 1. Briefly, measurements will include the
aortic diameter, and the aortic area of both true lumen and
false lumen at 4 specified anatomical sites (ascending
aorta, origin of the left subclavian artery, 10 cm distal to
the origin of the left subclavian artery and the origin of the
celiac trunk). The true lumen index, the false lumen index
and the true/false lumen ratio will be calculated. The state
of the false lumen in terms of thrombosis (patent, partially
thrombosed or thrombosed) will be documented.
Statistical analysis
Statistical analysis was performed with the SAS System
Version 9.2 TS level 2M2.
One way ANOVA was used to analyse continuous data.
The KruskalleWallis analysis was used to analyse the SVSscore. The Fisher Exact test was used to analyse other
discrete variables. Significance was assumed at a p value of
0.05.
Results
Patient cohort and demographics
100 Patients were recruited to the Virtue registry between
5 December 2006 and 26 August 2009. Fifty patients had an
acute dissection, 24 a sub-acute dissection and 26 a chronic
lesion. The patient demographics are illustrated in Table 2.
There were little differences between the three groups
with respect to traditional risk factors of co-morbidities.
One notable exception was abdominal aortic aneurysms
that were present in 26.9% of the patients with a chronic
dissection as compared to 8% and 4.2% of the acute and sub-
acute groups respectively.
The indications for endovascular repair of the Type B
dissections are illustrated in Table 3. As expected the
majority of patients in the acute and sub-acute group had
complicated dissections. The chronic group had a much
lower incidence of complication and repair was most often
mandated for aortic expansion. The site of malperfusion
was documented for the acute and sub-acute dissections. In
the patients with complicated acute Type B dissection the
organ affected by malperfusion syndrome (16 patients out
of 50) was the spinal cord in 35%, the intestines in 40%, the
kidneys in 65% and the lower limbs in 25%. For the sub-acute
group, 8 patients had a malperfusion syndrome affecting
the intestines in 12.5%, the kidneys in 87.5% and the lower
limbs in 25%.
Procedural details
The proximal landing zone for the 100 patients was Ishimaru
zone 0 in 4, zone 1 in 7, zone 2 in 37 and zone 3 in 52.
Adjunctive surgical procedures included total arch
debranching (ascending aortic to innominate, left common
carotid artery bypass, and left carotid-subclavian bypass) in
4 (with aortic root replacement in 3); carotid to carotid
bypass in 7 (4 with associated carotid-left subclavian artery
Figure 1 Photograph of the Valiant stent graft. Note the
8-peaked spring on the FreeFlo design.
162 The VIRTUE Registry Investigatorsbypass), and isolated left common carotid to left subclavian
artery bypass in 15 patients. In addition there were 2
concomitant abdominal aortic aneurysm repairs. The
patients who had ascending aortic repair has a dilated but
non-dissected ascending aorta with a distal dissection. No
patient in this group had an aortic valve replacement.
The details of the endovascular procedures are tabu-
lated in Table 4. The adjunctive endovascular procedures
included stents to the renal arteries in 5, the superior
mesenteric artery in 1, iliac artery in 1 and 3 endovascular
fenestrations. In addition there were 2 patients who
required a laparotomy for ischaemic gut.
30-Day (in hospital) outcomes
The 30-day and in hospital (if greater than 30 days)
outcomes for the three groups of patients is documented
in Table 5. The only early mortality was in the patients with
complicated acute Type B dissection. The 30-day deaths in
the acute group contained two patients with sudden death
4 h and 11 days post-operatively. Post mortem examinationdid not reveal an obvious cause of death in either case. The
last two 30-day deaths were from a myocardial infarction
on post-operative days 10 and 17. Two further deaths
occurred in hospital after 30 days. One patient died from
paraplegia, subsequent respiratory failure, stroke and
multi-organ failure. The final mortality was from ongoing
intestinal ischaemia in a patient who presented with
intestinal malperfusion.
There were 4 strokes in the acute group. All strokes were
in the middle cerebral artery territory, and all occurred
within 1 day of the index endovascular procedure.
In terms of timing, both cases of paraplegia also
occurred on the first post-operative day.
The endograft related outcomes and complications are
documented in Table 6.
There were 2 technical failures due to an early mortality
in the acute group and a graft kink requiring a second stent
at a separate procedure in the chronic group.
Management of the left subclavian artery
The left subclavian artery was covered by the endovascular
graft in 48 patients, and was revascularised pre-operatively
in 23 patients (4 total arch debranching with left subclavian
bypass, 4 carotid-carotid-left subclavian bypass and 15 left
carotid-subclavian bypass). The outcomes for patients
according to the status of the left subclavian artery are
illustrated in Table 7. Although there is a trend towards
a worse composite outcome in the patients with a non-
revascularised, covered left subclavian artery, there is no
statistical significance. There are too few patients to
perform an analysis based on disease group.
Discussion
The Virtue registry reports a series of 100 patients having
undergone endovascular repair of Type B aortic dissection
with the Valiant endograft. The registry has been divided
by the duration of the dissection, with outcomes being
reported for acute, sub-acute and chronic lesions. The
registry will report early and long term clinical and
morphological data for these three groups of patients for up
to three years follow-up. The current report is concerned
with the patient cohort and early outcomes of endovascular
therapy. Subsequent reports will detail the long term
disease and endograft related complications and will also
define the aortic response to endovascular therapy in terms
of aortic remodelling and requirement for reintervention.
The three groups of patients in this study had established
indications for endovascular therapy. All of the patients in
the acute groupwere recruited on the basis of a complicated
dissection, with rupture, impending rupture, malperfusion
or refractory hypertension. These are well-accepted indi-
cations for repair of an acute Type B dissection. No patients
with asymptomatic or uncomplicated acute dissections were
entered into the registry. Patients with chronic dissection
generally had significant aortic expansion whilst the sub-
acute group was a mixed group containing a substantial
number of complicated dissections but also some patients
with clinically significant aortic expansion. In defining the
indications for endovascular therapy in the sub-acute group,
Table 2 Patient demographics.
Acute (50) Sub-Acute (24) Chronic (26) p
Age (mean SD) 62.7 (14.1) 59.2 (11.0) 58.3 (10.9) NS
Male gender (%) 38 (76.0%) 18 (75.0%) 20 (76.9%) NS
IHD SVS 2/3 (%) 7 (14) 3 (12.5) 4 (15.3) NS
Cardiac failure (%) 0 (0) 1 (4.2) 1 (3.8) NS
Hypertension SVS 2/3 (%) 28 (56) 17 (70.9) 24 (92.3) NS
COPD (%) 7 (14) 4 (16.7) 3 (11.5) NS
Renal status SVS 2/3 (%) 1 (2) 3 (12.5) 1 (3.8) NS
Diabetes SVS 2/3 (%) 0 (0) 1 (4.2) 0 (0) NS
Ascending aortic aneurysm (%) 3 (6) 3 (12.5) 2 (7.6) NS
Abdominal aortic aneurysm (%) 4 (8) 1 (4.2) 7 (26.9) 0.02
Peripheral aneurysm (%) 1 (2) 0 (0) 0 (0) NS
Type A dissection (%) 0 (0) 2 (8.3) 0 (0) NS
Carotid SVS 2/3 (%) 2 (4) 0 (0) 0 (0) NS
Mean SVS Score (SD) 2.1 (1) 2.1 (1) 2.4 (0.7) NS
IHD: ischaemic heart disease; SVS: Society for vascular surgery grading system for common risk factors; COPD: chronic obstructive
pulmonary disease; Type A dissection: previous history of Type A dissection (repaired).
Figure 2 The Xcelerant delivery system.
The VIRTUE Registry of Type B Thoracic Dissections 163there was a group of patients who underwent repair on the
basis of an aortic diameter exceeding 4 cm in the presence of
a patent false lumen. This indication for surgery would be
considered relative,6 but there exists some evidence thatTable 3 Indications for endovascular repair.
Indication for surgery
Acute (n Z 50) Rupture
Limb or visceral ischae
Persisting pain
Uncontrolled hypertens
Sub-acute (n Z 24) Diameter > 4 cm
Expansion > 5.5 cm
Pain
Malperfusion
Rupture
Chronic (n Z 26) Expansion > 5.5 cm
Increase > 0.5 cm
Malperfusion
Rupture
Patients had more than one indication for endovascular repair in allthese patients have a high incidence of progression to either
complicated dissection or an aortic diameter above
5.5 cm7,8. There were few demographic differences
between the three groups, with the exception of theNumber %
11 22.0
mia 16 32.0
32 64.0
ion 8 16.0
9 37.5
3 12.5
5 20.8
8 33.3
1 4.2
13 50.0
13 50.0
2 7.7
1 3.8
three groups.
Table 5 30-Day and in hospital outcomes.
Acute (50) Sub-Acute (24) Chronic (26)
Mortality at 30 days 4 (8) 0 (0) 0 (0)
30-d þ in hospital mortality 6 (12) 0 (0) 0 (0)
Stroke/CVA at 30 days 4 (8) 0 (0) 0 (0)
Spinal cord ischaemia (30d) 1 (2) 0 (0) 1 (3.8)
Composite endpoint (30d) 8 (16) 0 (0) 1 (3.8)
Composite outcome is defined by mortality or paraplegia or stroke.
Absolute numbers are shown with percentages in parentheses.
Table 4 Procedural details.
Acute (50) Sub-Acute (24) Chronic (26)
Number stents 1.6 (0.7) 1.5 (0.5) 1.8 (0.8)
Length aorta covered (mm) 151.2 (23.5) 166.2 (33.4) 164.1 (27.2)
Duration of procedure (min) 134.0 (83.9) 135.9 (91.5) 143.8 (67.2)
Contrast volume (ml) 171.6 (79.9) 136.6 (55.5) 153.6 (51.8)
Time in ITU (h) 154.3 (211.2) 75.2 (87.5) 38.9 (33.3)
Hospital stay (d) 18.4 (19.7) 19.6 (19.2) 14.5 (13.5)
Blood transfusion (no. patients) 6 (12.0%) 1 (4.2%) 1 (3.8%)
All values mean (SD).
164 The VIRTUE Registry Investigatorspresence of abdominal aortic aneurysms in 27% of the
chronic group. Abdominal involvement in the patients with
chronic dissection has been recognised previously4 and is
indicative of the requirement to consider management of
the entire aorta in patients with chronic Type B aortic
dissection.
The cohort of patients in this registry had reasonably
complex proximal landing zones with 48 endografts
covering the left subclavian artery and 11 patients having
a proximal landing zone over the left common carotid
artery. Interestingly, there was no difference in the length
of aorta covered between the three groups. This would
suggest that the clinicians involved in the present study did
not cover more aorta in chronic dissections as has been
suggested previously,4 or it may reflect that all the acute
dissections were complicated and so a greater length of
aorta was covered than just the proximal tear.
The main findings of the registry reported here were the
early outcomes in the three groups. The only early deaths
were in the acute dissection group, where the mortality (in
patient) was 12%. Disparate outcomes in the endovascularTable 6 Procedural outcomeseendograft.
Acute (50)
Technical success 49 (98)
Type I endoleak 1 (2)
Type III endoleak 0 (0)
Retrograde Type A dissection 0 (0)
Absolute numbers are shown with percentages in parentheses.
Technical success defined by: - Unsuccessful stent graft introduction.
the proximal entry tear. - Immediate conversion to open surgery du
period. - Presence of graft significant twist, kink or obstruction by intreatment of acute and chronic dissections have been
reported previously.9 In a meta-analysis of 609 patients,
Eggebrecht et al.10 described a 9.8% 30-day mortality in
patients with acute dissection in comparison to 3.2% with
chronic disease. The same author11 reported a single centre
series of 38 patients in which the early mortality in the
acute group was 40%, with no mortality in patients with
chronic disease.
However, other authors have reported an inverse trend.
Guangqi et al.12 revealed the outcomes of 121 patients with
a 1.4% mortality in acute patients in contrast to a 8.2%
mortality in the chronic group. Similarly, Rodriguez et al.13
reported a 1% vs. 7% mortality in favour of the acute group.
It seems likely that the mortality for acute dissections will
be particularly determined by the case mix and in the
number of complicated versus uncomplicated dissections,
and the proportion of patients who had malperfusion and/
or rupture. In the present series over 50% of the patient
had either rupture or malperfusion and a 30-day mortality
of 6% appears in line with previous series for this compli-
cated group of patients.14 As in previous reports, there isSub-Acute (24) Chronic (26)
24 (100) 25 (96.2)
0 (0) 0 (0)
0 (0) 0 (0)
0 (0) 0 (0)
- Unsuccessful stent graft deployment. - Unsuccessful coverage of
ring the same intervention. - Death within 24 h post-operative
tra-operative measurements.
Table 7 Procedural outcomes LSCA.
LSCA not covered
(n Z 52)
LSCA covered
Revascularised
(n Z 23)
LSCA covered Not
Revascularised
(n Z 25)
Mortality at 30 days 2 (3.8) 0 (0) 2 (8.0)
30-d þ in hospital mortality 3 (5.8) 0 (0) 3 (12)
Stroke/CVA at 30 days 1 (1.9) 1 (4.3) 2 (8.0)
Spinal cord ischaemia (30d) 0 (0) 0 (0) 2 (8.0)
Composite endpoint (30d) 3 (5.8) 1 (4.3) 5 (20.0)
Composite outcome is defined by mortality or paraplegia or stroke.
Absolute numbers are shown with percentages in parentheses.
The VIRTUE Registry of Type B Thoracic Dissections 165a significant incidence of stroke after the endovascular
treatment of acute complicated aortic dissection.15 The
registry data give further credence to the evolving treat-
ment algorithm that endovascular management of acute
complicated dissection has a significant advantage over
open surgical techniques.16,17
The early outcomes of the patients with chronic and sub-
acute dissections were excellent with no mortality and one
episode of spinal cord ischaemia. However, early outcomes
in these groups have been reported previously6,9 and it is
likely to be the ability of endovascular techniques to prevent
rupture in the long term that is important. This will only
become apparent after longer follow-up, which will also
define morphological changes and the reintervention rates.
The management of the left subclavian artery was
detailed in this report. Forty eight percent of the patients
in the registry had coverage of the left subclavian artery.
There was no prescribed management of the left subclavian
artery but 23/48 patients had the subclavian revascularised
prior to the endovascular procedure. Although there was no
statistical significance, there was a trend towards better
outcomes in the patients who underwent revascularisation,
who had a composite outcome of 5.8% as compared to 20%
in the non-revascularised group. These results will provide
further data for subsequent meta-analyses and systematic
reviews of the role of left subclavian artery management in
endovascular procedures on the thoracic aortic arch. At
present there is a developing body of evidence that would
suggest that revascularisation of covered left subclavian
arteries offers protection against a composite endpoint of
stroke, paraplegia and death.18,19
The early outcomes of the Virtue registry provide high
quality validated data regarding the endovascular treatment
of Type B aortic dissection as applied to a group of patients
with robust indications for therapy. The data demonstrate
worse outcomes in the acute group as compared to patients
with sub-acute or chronic dissections. Long term data will
provide much needed evidence regarding the ability of
endovascular therapy to prevent aortic dilatation and
rupture in the long term. Core lab data will inform on aortic
remodelling following endovascular repair and will also
provide information of late reintervention.
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